Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- INES-Led Coalition Calls for Patient/Citizen Participation in Healthcare Policymaking
May 23, 2022
- Japan, US, European Pharma Groups Prod Price Maintenance of Patented Drugs in Joint Pitch towards Honebuto
May 17, 2022
- PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
- JPMA Takes Issue with WTO IP Waiver Proposal for COVID Vaccines
May 13, 2022
- Lagevrio Given to 87,000 via Pharmacies, Paxlovid to 120 as of April 15
May 9, 2022
- FPMAJ Official Prods Rethink of Off-Year Price Revision as Ukraine War Pushes Up Costs
April 27, 2022
- JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
April 27, 2022
- JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
April 25, 2022
- Predictability of Drug Pricing Must Be Ensured: EFPIA Japan Director General
April 22, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- FPMAJ Looks into Impact of Shanghai COVID-19 Lockdown
April 11, 2022
- Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
April 7, 2022
- Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
April 6, 2022
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
- Stop Avigan Stockpiling, Revoke Flu Approval: Drug Damage Watchdog
April 5, 2022
- JPMA to Push Innovation Cycle, Ponder Next-Gen Pricing System: FY2022 Project Plan
April 5, 2022
- Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
- Generic Use Rate Treads Water at 79.3% in October-December: JGA
April 4, 2022
- FPMAJ Poll Finds 65% Self-Inspection Rate for “Stable Supply Medicines”
March 28, 2022
- FPMAJ Hammers Out FY2022 Project Plans, Revs Up for Off-Year Revision Debate
March 28, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…